1-12 of 12
Yves Fradet
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

Aude Fléchon, Rafael Morales-Barrera, Thomas Powles, Ajjai Alva, Mustafa Özgüroğlu, Tibor Csöszi, Yohann Loriot, Alejo Rodriguez-Vida, Lajos Géczi, Susanna Y. Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Seyda Gunduz, Ronac Mamtani, Evan Y. Yu, Alvaro Montesa Pino, Urbano Anido, Mehmet A.N. Sendur, Gwenaelle Gravis, János Révész, Vladimir Kostorov, Olivier Huillard, Junshui Ma, Mohini Rajasagi, Amir Vajdi, Jared Lunceford, Razvan Cristescu, Kentaro Imai, Blanca Homet Moreno, Nobuaki Matsubara
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (23): 5353–5364.
https://doi.org/10.1158/1078-0432.CCR-23-3518
Published: 02 December 2024
View article titled, Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
Open the PDF for Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2050–2060.
https://doi.org/10.1158/1078-0432.CCR-21-3089
Published: 13 May 2022
View article titled, Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Open the PDF for Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials in another window
Includes: Supplementary data
Journal Articles

Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial

Paul Toren, Azik Hoffman, Keyue Ding, France-Hélène Joncas, Véronique Turcotte, Patrick Caron, Frédéric Pouliot, Yves Fradet, Éric Lévesque, Chantal Guillemette, Laurence Klotz
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (21): 5305–5312.
https://doi.org/10.1158/1078-0432.CCR-18-1187
Published: 01 November 2018
View article titled, Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A <em>Post Hoc</em> Analysis of the PR.7 Trial
Open the PDF for Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A <em>Post Hoc</em> Analysis of the PR.7 Trial in another window
Includes: Supplementary data
Journal Articles

Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study

Daniel J. Sargent, Qian Shi, Sharlene Gill, Christophe Louvet, Richard B. Everson, Udo Kellner, Thomas E. Clancy, J. Marc Pipas, Murray B. Resnick, Michael O. Meyers, Tsung-Teh Wu, David Huntsman, Pierre Validire, Umar Farooq, Emily S. Pavey, Guillaume Beaudry, Jean-Francois Haince, Yves Fradet
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4361–4369.
https://doi.org/10.1158/1078-0432.CCR-13-2659
Published: 13 August 2014
View article titled, Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study
Open the PDF for Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study in another window
Includes: Supplementary data
Journal Articles

Steroidogenic Germline Polymorphism Predictors of Prostate Cancer Progression in the Estradiol Pathway

Éric Lévesque, Isabelle Laverdière, Étienne Audet-Walsh, Patrick Caron, Mélanie Rouleau, Yves Fradet, Louis Lacombe, Chantal Guillemette
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 2971–2983.
https://doi.org/10.1158/1078-0432.CCR-13-2567
Published: 29 May 2014
View article titled, Steroidogenic Germline Polymorphism Predictors of Prostate Cancer Progression in the Estradiol Pathway
Open the PDF for Steroidogenic Germline Polymorphism Predictors of Prostate Cancer Progression in the Estradiol Pathway in another window
Includes: Supplementary data
Journal Articles

Importance of 5α-Reductase Gene Polymorphisms on Circulating and Intraprostatic Androgens in Prostate Cancer

Éric Lévesque, Isabelle Laverdière, Louis Lacombe, Patrick Caron, Mélanie Rouleau, Véronique Turcotte, Bernard Têtu, Yves Fradet, Chantal Guillemette
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (3): 576–584.
https://doi.org/10.1158/1078-0432.CCR-13-1100
Published: 02 February 2014
View article titled, Importance of 5α-Reductase Gene Polymorphisms on Circulating and Intraprostatic Androgens in Prostate Cancer
Open the PDF for Importance of 5α-Reductase Gene Polymorphisms on Circulating and Intraprostatic Androgens in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression

Éric Lévesque, Shu-Pin Huang, Étienne Audet-Walsh, Louis Lacombe, Bo-Ying Bao, Yves Fradet, Isabelle Laverdière, Mélanie Rouleau, Chao-Yuan Huang, Chia-Cheng Yu, Patrick Caron, Chantal Guillemette
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (3): 699–709.
https://doi.org/10.1158/1078-0432.CCR-12-2812
Published: 31 January 2013
View article titled, Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression
Open the PDF for Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression in another window
Includes: Supplementary data
Journal Articles

The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder

Robert S. Svatek, Shahrokh F. Shariat, Robert E. Lasky, Eila C. Skinner, Giacomo Novara, Seth P. Lerner, Yves Fradet, Patrick J. Bastian, Wassim Kassouf, Pierre I. Karakiewicz, Hans-Martin Fritsche, Stefan C. Müller, Jonathan I. Izawa, Vincenzo Ficarra, Arthur I. Sagalowsky, Mark P. Schoenberg, Arlene O. Siefker-Radtke, Randall E. Millikan, Colin P.N. Dinney
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (17): 4461–4467.
https://doi.org/10.1158/1078-0432.CCR-10-0457
Published: 31 August 2010
View article titled, The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder
Open the PDF for The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder in another window
Journal Articles

Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study

Shahrokh F. Shariat, Pierre I. Karakiewicz, Guilherme Godoy, Jose A. Karam, Raheela Ashfaq, Yves Fradet, Hendrik Isbarn, Francesco Montorsi, Claudio Jeldres, Patrick J. Bastian, Matthew E. Nielsen, Stefan C. Mller, Arthur I. Sagalowsky, Yair Lotan
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (22): 7012–7019.
https://doi.org/10.1158/1078-0432.CCR-08-2554
Published: 11 November 2009
View article titled, Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study
Open the PDF for Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study in another window
Journal Articles

Intravesical Chemotherapy of High-Grade Bladder Cancer with HTI-286, A Synthetic Analogue of the Marine Sponge Product Hemiasterlin

Boris A. Hadaschik, Hans Adomat, Ladan Fazli, Yves Fradet, Raymond J. Andersen, Martin E. Gleave, Alan I. So
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1510–1518.
https://doi.org/10.1158/1078-0432.CCR-07-4475
Published: 03 March 2008
View article titled, Intravesical Chemotherapy of High-Grade Bladder Cancer with HTI-286, A Synthetic Analogue of the Marine Sponge Product Hemiasterlin
Open the PDF for Intravesical Chemotherapy of High-Grade Bladder Cancer with HTI-286, A Synthetic Analogue of the Marine Sponge Product Hemiasterlin in another window
Journal Articles

Reproducibility of p53 Immunohistochemistry in Bladder Tumors

Lisa M. McShane, Roger Aamodt, Carlos Cordon-Cardo, Richard Cote, David Faraggi, Yves Fradet, H. Barton Grossman, Amy Peng, Sheila E. Taube, Frederic M. Waldman, the National Cancer Institute Bladder Tumor Marker Network
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (5): 1854–1864.
Published: 01 May 2000
View article titled, Reproducibility of p53 Immunohistochemistry in Bladder Tumors
Open the PDF for Reproducibility of p53 Immunohistochemistry in Bladder Tumors in another window
Journal Articles

Predictive Value of Cell Cycle Markers p53, MDM2, p21, and Ki-67 in Superficial Bladder Tumor Recurrence

Christian Pfister, Lynne Moore, Pierre Allard, Hélène Larue, Louis Lacombe, Bernard Têtu, François Meyer, Yves Fradet
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (12): 4079–4084.
Published: 01 December 1999
View article titled, Predictive Value of Cell Cycle Markers p53, MDM2, p21, and Ki-67 in Superficial Bladder Tumor Recurrence
Open the PDF for Predictive Value of Cell Cycle Markers p53, MDM2, p21, and Ki-67 in Superficial Bladder Tumor Recurrence in another window